Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients

ID
Name
19-1731
Description
This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
Trial arms
Trial start
2020-06-01
Estimated PCD
2023-12-31
Trial end
2024-01-31
Status
Terminated
Treatment
Dalbavancin
Dalbavancin 1500 mg intravenously x 1 dose
Size
2
Primary endpoint
Clinical cure
14 days
Clinical cure
28 days
Eligibility criteria
Inclusion Criteria: Patients \> 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending. Exclusion Criteria: Patients with contraindications to dalbavancin therapy
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 2, 'type': 'ACTUAL'}}
Updated at
2024-05-09

1 organization

1 product

1 indication

Organization
University of Colorado Denver
Product
Dalbavancin
Indication
Peritonitis